SK288016B6 - Use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1- yl)-ethyl]-2,2-diphenylacetamide or its salt as hydrochloride for the manufacture of a medicament for the treatment of Irritable Bowel Syndrome. - Google Patents

Use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1- yl)-ethyl]-2,2-diphenylacetamide or its salt as hydrochloride for the manufacture of a medicament for the treatment of Irritable Bowel Syndrome. Download PDF

Info

Publication number
SK288016B6
SK288016B6 SK5006-2008A SK50062008A SK288016B6 SK 288016 B6 SK288016 B6 SK 288016B6 SK 50062008 A SK50062008 A SK 50062008A SK 288016 B6 SK288016 B6 SK 288016B6
Authority
SK
Slovakia
Prior art keywords
phenyl
methyl
ethyl
hydroxypyrrolidin
salt
Prior art date
Application number
SK5006-2008A
Other languages
English (en)
Slovak (sk)
Inventor
Andreas Bathe
Bernd Helfert
Karl-August Ackermann
Rudolf Gottschlich
Ingeborg Stein
Jens Budak
Original Assignee
Tioga Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7865063&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288016(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tioga Pharmaceuticals, Inc. filed Critical Tioga Pharmaceuticals, Inc.
Publication of SK288016B6 publication Critical patent/SK288016B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/02—Reduction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK5006-2008A 1998-04-20 1999-04-16 Use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1- yl)-ethyl]-2,2-diphenylacetamide or its salt as hydrochloride for the manufacture of a medicament for the treatment of Irritable Bowel Syndrome. SK288016B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19817393 1998-04-20
DE19827633A DE19827633A1 (de) 1998-04-20 1998-06-20 Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
PCT/EP1999/002574 WO1999054298A1 (de) 1998-04-20 1999-04-16 Verfahren zur herstellung von enantiomerenreinem n-methyl- n-[(1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid

Publications (1)

Publication Number Publication Date
SK288016B6 true SK288016B6 (sk) 2012-11-05

Family

ID=7865063

Family Applications (2)

Application Number Title Priority Date Filing Date
SK5006-2008A SK288016B6 (sk) 1998-04-20 1999-04-16 Use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1- yl)-ethyl]-2,2-diphenylacetamide or its salt as hydrochloride for the manufacture of a medicament for the treatment of Irritable Bowel Syndrome.
SK1557-2000A SK286442B6 (sk) 1998-04-20 1999-04-16 Spôsob prípravy N-metyl-N-[(1S)-1-fenyl-2-((3S)-3- hydroxypyrolidin-1-yl)etyl]-2,2-difenylacetamidu

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK1557-2000A SK286442B6 (sk) 1998-04-20 1999-04-16 Spôsob prípravy N-metyl-N-[(1S)-1-fenyl-2-((3S)-3- hydroxypyrolidin-1-yl)etyl]-2,2-difenylacetamidu

Country Status (28)

Country Link
US (1) US6344566B1 (es)
EP (2) EP1607090B1 (es)
JP (1) JP4688292B2 (es)
KR (1) KR100649175B1 (es)
CN (2) CN1310884C (es)
AR (2) AR019080A1 (es)
AT (2) ATE303361T1 (es)
AU (2) AU761721B2 (es)
BR (1) BR9909731A (es)
CA (1) CA2329210C (es)
CY (1) CY1112314T1 (es)
CZ (1) CZ301121B6 (es)
DE (2) DE19827633A1 (es)
DK (2) DK1607090T3 (es)
ES (2) ES2375384T3 (es)
HK (1) HK1039111A1 (es)
HU (1) HUP0101600A3 (es)
MY (1) MY120471A (es)
NO (1) NO317984B1 (es)
PL (1) PL206969B1 (es)
PT (1) PT1607090E (es)
RU (1) RU2298549C2 (es)
SI (2) SI1607090T1 (es)
SK (2) SK288016B6 (es)
TW (1) TWI249524B (es)
UA (1) UA73472C2 (es)
WO (1) WO1999054298A1 (es)
ZA (1) ZA200006689B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
US20070160559A1 (en) * 2006-01-12 2007-07-12 Roszell James A Skin disinfectant composition and methods for using
AU2008232954A1 (en) * 2007-03-30 2008-10-09 Tioga Pharmaceuticals Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN112574068A (zh) * 2020-11-17 2021-03-30 万华化学（宁波）有限公司 一种低色号高稳定性碳化二亚胺改性异氰酸酯的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
US5968968A (en) * 1996-07-24 1999-10-19 Warner-Lambert Company Diphenyl-cyclopropenes as selective K-agonists
DE19647538A1 (de) * 1996-11-16 1998-05-20 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Also Published As

Publication number Publication date
NO317984B1 (no) 2005-01-17
PL206969B1 (pl) 2010-10-29
RU2298549C2 (ru) 2007-05-10
AU4031199A (en) 1999-11-08
WO1999054298A1 (de) 1999-10-28
AR019080A1 (es) 2001-12-26
DE19827633A1 (de) 1999-10-21
KR20010042750A (ko) 2001-05-25
HUP0101600A2 (hu) 2001-09-28
MY120471A (en) 2005-10-31
BR9909731A (pt) 2000-12-19
JP2002512223A (ja) 2002-04-23
CN1310884C (zh) 2007-04-18
SK15572000A3 (sk) 2001-05-10
CN1297435A (zh) 2001-05-30
HUP0101600A3 (en) 2002-12-28
AU761721B2 (en) 2003-06-05
NO20005259D0 (no) 2000-10-19
ATE527999T1 (de) 2011-10-15
ES2375384T3 (es) 2012-02-29
DK1607090T3 (da) 2012-01-30
CN1846696A (zh) 2006-10-18
TWI249524B (en) 2006-02-21
CZ20003860A3 (cs) 2001-01-17
PT1607090E (pt) 2012-01-10
CZ301121B6 (cs) 2009-11-11
EP1073634B1 (de) 2005-08-31
ES2251194T3 (es) 2006-04-16
PL343556A1 (en) 2001-08-27
US6344566B1 (en) 2002-02-05
CA2329210A1 (en) 1999-10-28
DE59912502D1 (de) 2005-10-06
SK286442B6 (sk) 2008-10-07
AU2003248428B2 (en) 2005-10-20
NO20005259L (no) 2000-10-19
ZA200006689B (en) 2002-02-18
KR100649175B1 (ko) 2006-11-24
CA2329210C (en) 2008-03-04
CY1112314T1 (el) 2015-12-09
UA73472C2 (en) 2005-08-15
AU2003248428A1 (en) 2003-11-06
EP1073634A1 (de) 2001-02-07
JP4688292B2 (ja) 2011-05-25
AR066455A2 (es) 2009-08-19
ATE303361T1 (de) 2005-09-15
EP1607090A1 (de) 2005-12-21
SI1607090T1 (sl) 2012-01-31
HK1039111A1 (en) 2002-04-12
SI1073634T1 (sl) 2006-02-28
DK1073634T3 (da) 2006-01-09
EP1607090B1 (de) 2011-10-12

Similar Documents

Publication Publication Date Title
SK288016B6 (sk) Use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1- yl)-ethyl]-2,2-diphenylacetamide or its salt as hydrochloride for the manufacture of a medicament for the treatment of Irritable Bowel Syndrome.
NO150139B (no) Kompileringsapparat.
US6294557B1 (en) Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
US4436740A (en) 3-Cycloalkylamino-2-OR-propoxycyanopyridines
US6172234B1 (en) Optically active cyclic amino acid ester derivatives and processes for producing the same
MXPA00010234A (es) Procedimiento para preparar el enantiomero puro de n-metil-n- [(1s)-1- fenil-2- ((3s)-3-hidroxipirrolidin- 1-il) etil]-2,2-difenilacetamida
EP0079740B1 (en) Anthraniloyloxyalkanoates
US20060084807A1 (en) Novel denzamide derivatives and process for production thereof
EP1698621A1 (en) Method for producing pyrrolidine derivative
EP1461317A2 (en) Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150416